Abstract
Multiple myeloma (MM) is a B cell neoplasia that accounts for 10% of all hematological tumors. Despite the progress in MM therapies most patients still relapse. CAR-T cell therapy with anti-BCMA (a receptor expressed exclusively by mature B and MM cells), are able to increase patient survival and delay relapses. Although there are some approved CAR-T therapy in agencies such as the FDA, a…